Risk – Reward of Developing a Herceptin Biosimilar – A Thorough Assessment

Date: 2015-07

“Herceptin exclusivity is expiring in major geographies and many Biosimilar players (both experienced and new entrant) are looking to have a share of this potential $6billion pie. Herceptin sales are critical to Roche as it comprise about 15% of its cumulative Pharma sales. While eying for this potential lucrative opportunity, there are several risks and barriers that Biosimilar players should be aware. The report – “Risk – Reward of Developing a Herceptin biosimilar – A thorough assessment” looks into several aspects of potential opportunity size for Biosimilar players, with regard to:
– European Experience of Biosimilars

– Current market positioning of Herceptin across geography

– Different technologies deployed by biosimilar players

– Competition – Pipeline of Biosimilar and Biobetters targeting Herceptin

– Potential Market Expansion post expiry of Market Exclusivity

– Defense Strategies deployed by Roche

– Ongoing Clinical trials and their impact on Market Opportunity

– Global Regulatory Process and Hurdles

– Risk/Reward profile of developing Herceptin biosimilar

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample